Similarly, a recent report suggested that GLP1 agonists when administered to T2D patients with concurrent cardiovascular disease, lead to significant reduction of hospitalizations, as well as kept bone metabolism unaffected [53]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.